Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27103100 | 0.84 | LRRK2 (0.36) | FGFR1PDGFRBPDGFRASRCLRRK2 | |
| SCHEMBL27103167 | 0.83 | ABL1 (0.43) | ADORA3ADORA1 | |
| SCHEMBL27103166 | 0.80 | ALDH1A1 (0.46) | FGFR1CYP1A2PIK3CAMAP3K5TP53 | |
| SCHEMBL24457928 | 0.76 | FGFR1 (0.47) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL27103103 | 0.71 | FLT3 (0.39) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL12862999 | 0.71 | FGFR1 (0.56) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL24457853 | 0.70 | FGFR1 (0.40) | FGFR1SRCEGFR | |
| SCHEMBL27103106 | 0.69 | PRKCH (0.35) | FGFR1SRCEGFR | |
| SCHEMBL8133798 | 0.69 | FGFR1 (0.61) | FGFR1PDGFRBPDGFRASRCEGFR | |
| SCHEMBL27103104 | 0.69 | TYRO3 (0.35) | LRRK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | FGFR1 739/4885PDGFRB 2779/4885PDGFRA 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.